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Circulating  antinuclear  antibodies  (ANA)  are  commonly  present  in  the  systemic  autoimmune  disease
Systemic  Lupus  Erythematosus  (SLE)  and  in other  systemic  rheumatic  diseases,  in humans  as  well  as  in
dogs. The  indirect  immunoﬂuorescence  (IIF)-ANA  test  is the  standard  method  for  detecting  ANA.  Further
testing  for speciﬁc  ANA  with  immunoblot  techniques  or ELISAs  is  routinely  performed  in  humans  to
aid  in  the  diagnosis  and monitoring  of  disease.  Several  speciﬁc  ANA  identiﬁed  in  humans  have been
identiﬁed  also  in  suspected  canine  SLE  but,  in  contrast  to  humans,  investigation  of autoantibodies  in
canine  SLE  is mainly  restricted  to the  IIF-ANA  test.  Our  aim  was  to  identify  both  known  and novel  speciﬁc
ANA  in  dogs  and  to investigate  if  different  IIF-ANA  patterns  are  associated  with  different  speciﬁc  ANA
in dogs.  Sera  from  240  dogs  with  suspicion  of autoimmune  disease  (210  IIF-ANA  positive  (ANApos)  and
30  IIF-ANA  negative  (ANAneg))  as  well  as  sera  from  27  healthy  controls  were  included.  The  samples
were  analysed  with  a line  immunoassay,  LIA  (Euroline  ANA Proﬁle  5, Euroimmun,  Lübeck,  Germany)
and  four  different  ELISAs  (Euroimmun).  The  ANApos dogs  were  divided  in  two  groups  depending  on  the
type of  IIF-ANA  pattern.  Of the  210  ANApos samples  68  were  classiﬁed  as  ANA  homogenous  (ANAH)  and
141  as  ANA  speckled  (ANAS),  one  sample  was  not  possible  to  classify.  Dogs  in  the  ANAH group had,
compared  to the  other  groups,  most  frequently  high  levels  of anti-double  stranded  deoxyribonucleic
acid  (dsDNA)  and  anti-nucleosome  ANA.  Anti-dsDNA  antibodies  were  conﬁrmed  in  some  dogs  with  the
Crithidia  luciliae  indirect  immunoﬂuorescence  test  (CLIFT).  The  frequency  of  ANAH dogs  with  values  above
those  observed  in  the healthy  group  was  signiﬁcantly  higher  compared  to  ANAS dogs  for  anti-dsDNA,  anti-
nucleosome,  and  anti-histone  reactivity.  Dogs  in  the  ANAS group  had,  compared  to the  other  groups,  most
frequently  high  levels  of  anti-ribonucleoproteins  (RNP)  and/or  anti-Smith  (Sm) antibodies.  Reactivity
against  Sjögren’s  syndrome  related  antigens  (SS)-A  (including  the  Ro-60  and  Ro-52  subcomponents),  SS-
B, histidyl  tRNA  synthetase  (Jo-1),  topoisomerase  I antigen  (Scl-70),  polymyositis-scleroderma  antigen
(PM-Scl)  and  proliferating  cell  nuclear  antigen  (PCNA)  was  also  noted  in  individual  dogs.  In conclusion,
by  using  a  commercial  LIA  and different  ELISAs  originally  developed  for detection  of human  ANA,  we
identiﬁed  several  speciﬁc  ANA  in  serum  samples  from  dogs  sampled  for  IIF-ANA  testing.  Further,  we
found  that  the  types  of IIF-ANA  pattern  were  associated  with  reactivity  against  some  particular  nuclear
antigens.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
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. Introduction
Antinuclear antibodies (ANA) represent a heterogeneous group
f autoantibodies directed at different nuclear antigens (Tan, 1989).
resence of high titres of ANA is a sensitive marker for the sys-
emic autoimmune disease Systemic Lupus Erythematosus (SLE) in
umans as well as in dogs (Tan et al., 1982; Bennett and Kirkham,
987; Monier et al., 1992). Antinuclear antibodies, and some
ytoplasmic autoantibodies, are also commonly present in other
ystemic rheumatic diseases (von Mühlen and Tan, 1995; Hansson-
amlin et al., 2006; Hansson-Hamlin and Lilliehöök, 2009) as well
s infrequently in healthy humans and dogs (Bennett and Kirkham,
987; Tan et al., 1997). Positive titres of ANA can sometimes also
e detected in canine leishmaniasis (Lucena et al., 1996), a dis-
ase that is rare in Sweden. The standard method for detecting
NA is indirect immunoﬂuorescence; IIF (Coons et al., 1950; Tan
t al., 1982; Bennett and Kirkham, 1987). In human diagnostics,
uman epithelial-2 (HEp-2) cells are commonly used as substrate
von Mühlen and Tan, 1995). In veterinary diagnostics, IIF-ANA test
ith HEp-2 cells are also used in the diagnosis of canine SLE and
anine SLE-related disorders (Hansson et al., 1996; Bell et al., 1997).
Antinuclear antibodies are directed against several differ-
nt antigens or groups of antigens such as double stranded
eoxyribonucleic acid (dsDNA), histones, Smith antigen (Sm),
ibonucleoproteins (RNP), Sjögren’s syndrome related antigens;
SS)-A/Ro, and SS-B/La (Tan, 1989). Several speciﬁc ANA previ-
usly identiﬁed in humans like the anti-histone (Costa et al., 1984;
onier et al., 1992), anti-RNP (Monier et al., 1978, 1980; Costa et al.,
984; Thoren-Tolling and Ryden, 1991; Fournel et al., 1992; Welin
enriksson et al., 1998; Hansson-Hamlin and Rönnelid, 2010), anti-
m (Monier et al., 1978; Costa et al., 1984; Hubert et al., 1988;
ournel et al., 1992), anti-SS-A (Monier et al., 1988; Fournel et al.,
992), and anti-SS-B (Monier et al., 1992) have been identiﬁed also
n suspected canine SLE cases. In addition, speciﬁc ANA against a
3 kDa protein known as the hnRNP G and against an unidentiﬁed
ntigen called type-2 antigen have been identiﬁed in dogs but not
n humans (Costa et al., 1984; Soulard et al., 1991; Fournel et al.,
992). Anti-dsDNA antibodies in canine SLE have only infrequently
een reported by some authors (Fournel et al., 1992; Monier et al.,
992).
Different IIF patterns are indicative of speciﬁc ANA (von Mühlen
nd Tan, 1995). Two common IIF patterns in humans are the
omogenous pattern and the speckled pattern. Other patterns are
lso recognised. A homogenous pattern is mainly associated with
eactivity against dsDNA and DNA associated proteins while a
peckled pattern is mainly associated with speciﬁc ANA against
NP, Sm,  SS-A, SS-B; also called extractable nuclear antigens; ENAs
Sharp et al., 1972; Tozzoli et al., 2002). The IIF-pattern and speciﬁc
NA can also be associated with different autoimmune disorders,
ome with high speciﬁcity for a particular disease (von Mühlen and
an, 1995). For example, the anti-dsDNA and anti-Sm antibodies are
uite speciﬁc for human SLE, and included in the diagnostic crite-
ia for human SLE (Tan et al., 1982; Hochberg, 1997). Some speciﬁc
NA, like the anti-dsDNA antibodies, are associated with particu-
ar symptoms and can correlate with disease activity (Kofﬂer et al.,
967; Swaak et al., 1986; Terborg et al., 1990). Hence, testing for
peciﬁc ANA is an aid in the diagnosis and monitoring of autoim-
une diseases in humans. Commonly used methods to screen for
peciﬁc ANA in humans are ELISA and immunoblot techniques
Tozzoli et al., 2002; Murdjeva et al., 2011). In order to investigate
nti-dsDNA antibodies, the Crithidia luciliae indirect immunoﬂuo-
escence test (CLIFT) is also a commonly used method (Aarden et al.,
975).
In contrast to humans where testing for speciﬁc ANA is routinely
erformed in suspected SLE cases, investigation of autoantibodies
n suspected canine SLE is mainly restricted to the IIF-ANA test Immunopathology 168 (2015) 233–241
(Bennett, 1987). The IIF-ANA test is almost always positive in canine
SLE, but a positive test alone is not sufﬁcient for the diagnosis.
Therefore, other clinical, haematological and/or biochemical alter-
ations also have to be present (Bennett, 1987). In dogs, two  distinct
immunoﬂuorescence patterns can be identiﬁed when using HEp-2
cells as a substrate (Fig. 1), the homogenous pattern, with chro-
mosomal staining of mitotic cells and the speckled pattern, with
non-chromosomal staining (Hansson and Karlsson-Parra, 1999).
The different patterns have been correlated with clinical signs in
dogs, suggesting that dogs with a homogenous pattern more often
show involvement of several organ systems than dogs with a speck-
led pattern (Hansson-Hamlin et al., 2006).
Today, even though there is some knowledge about speciﬁc ANA
in dogs, previous studies show that more research is needed in the
ﬁeld. The occurrence of some speciﬁc ANA that are of importance
in human medicine has not been investigated in dogs. Uniden-
tiﬁable ANA have also been found in dogs (Monier et al., 1980;
Costa et al., 1984; Hansson and Karlsson-Parra, 1999). Further,
very little is known about the clinical and pathological role of
speciﬁc ANA in dogs. In the present study we  investigated sera
from IIF-ANA tested dogs for speciﬁc ANA reactivity against sev-
eral antigens known to be associated with systemic autoimmune
or rheumatic disease in humans. Our aim was  to identify both
known and novel speciﬁc ANA in dogs and to investigate if differ-
ent IIF-ANA patterns are associated with different speciﬁc ANA in
dogs.
2. Materials and methods
2.1. Study design and study population
Included in the study were 210 IIF-ANA positive (ANApos) and
30 IIF-ANA negative (ANAneg) dog sera. The samples had been
submitted to the Clinical Pathology Laboratory, University Animal
Hospital, Uppsala, Sweden, from veterinarians all over Sweden for
routine IIF-ANA testing during May  2002–June 2012. Eight of the
dogs had been resampled 35–480 days from the ﬁrst sampling occa-
sion, so for these dogs two  serum samples were available. For the
majority of dogs included in the study, clinical information was  not
available, but the ANApos as well as the ANAneg dogs were assumed
to have a suspicion of autoimmune disease since the samples had
been sent for IIF-ANA testing.
The sera had been stored in −20 or −70 ◦C until analysis and
had been through two to four thaw–freeze cycles. The serum sam-
ples were sent to Euroimmun, Lübeck, Germany, where the IIF-ANA
tests were repeated. In order to detect speciﬁc ANA, two different
assays were performed, a line immunoassay (LIA) and an ELISA. As
a healthy control group, sera from 27 blood donor dogs and lab-
oratory dogs from Germany were also analysed. No information
about sex and breed was  available for these dogs. In total, 275 serum
samples from 267 dogs were investigated for IIF-ANA and for the
presence of speciﬁc ANA.
Conﬁrmatory analyses of ds-DNA reactivity with CLIFT were
performed in 39 of the diseased dog sera as well as in 12 healthy
control sera (collected from the Canine Biobank, SLU, Uppsala, eth-
ical permission C2/12).
The blood samples from the diseased dogs were initially taken
for diagnostic purposes (IIF-ANA tests) and for health screening for
the control dogs. An ethical permission was  obtained from the local
ethical committee, Uppsala, Sweden (C 418/12).2.2. IIF-ANA test
IIF-ANA tests were performed at the Clinical Pathology Labora-
tory, University Animal Hospital, Swedish University of Agricultural
H.D. Bremer et al. / Veterinary Immunology and Immunopathology 168 (2015) 233–241 235
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iig. 1. Picture illustrating two distinct immunoﬂuorescence patterns identiﬁed in d
ANA) pattern. Arrows are pointing at mitotic cells representing positive staining 
howing a negative staining of chromosomal regions surrounded by positive nucleo
ciences and at Euroimmun (Lübeck, Germany). Monolayers of
Ep-2 cells ﬁxed on glass slides (Immuno Concepts, Sacramento,
A, USA and Euroimmun, respectively) were incubated with sera
ccording to the manufacturer’s instructions as described pre-
iously (Hansson et al., 1996). The glass slides were examined
y ﬂuorescence microscopy and considered positive at a titre of
1:100. The visible nuclear ﬂuorescence pattern was divided into
wo groups; homogenous (ANAH) or speckled (ANAS) patterns as
reviously described (Hansson et al., 1996; Hansson-Hamlin et al.,
006). The samples from dogs with suspicion of autoimmune dis-
ase (ANApos and ANAneg dogs) were analysed for IIF-ANA positivity
oth in Sweden and in Germany, the samples from the healthy
ontrol dogs were only analysed in Germany. The type of IIF-ANA
attern was only reported by Euroimmun.
.3. Line immunoassay (Euroline ANA Proﬁle 5)
All the samples were analysed with the Euroline ANA Pro-
le 5 (Euroimmun) which is a line immunoassay (LIA), a type
f immunoblot, where recombinant antigens (RNP-A, RNP-C,
NP-70, SS-A/Ro-52, PM-Scl, centromere protein B (CENP B),
roliferation cell nuclear antigen (PCNA)) and native antigens
dsDNA, nucleosomes, histones, nRNP/Sm, Sm,  SS-A/Ro-60, SS-
/La, DNA topoisomerase I (Scl-70), histidyl tRNA synthetase
Jo-1), mitochondrial antigen 2 (M2), ribosomal P-proteins (RIB))
re coated as discrete lines on membrane chips with a plas-
ic backing (Schlumberger et al., 1995). Additionally one control
ine is coated on each strip. The assay was performed accord-
ng to the manufacturer’s instructions with the exception of the
nti-human-IgG conjugate, which was exchanged for alkaline
hosphatase-conjugated rabbit anti-dog IgG (Euroimmun). Brieﬂy,
he test sample was diluted 1:101 in the sample buffer provided. If
peciﬁc canine autoantibodies were present in the test serum, they
ound to the antigen containing lines on the strip. Anti-canine IgG
hen bound to any previously formed antigen/antibody complex.
ncubation with chromogen Nitroblue Tetrazolium Chloride/5-
romo-4-chloro-3-indolylphosphate (NBT/BCIP) produced a dark
lue colour proportional to the amount of speciﬁc antibody
resent in the test sample. Colour development was stopped
y adding distilled water after having discharged the substrate
olution. The strips were evaluated by automated examination
sing a ﬂatbed scanner and the EuroLineScan software (Euroim-
un) and quantiﬁcation was performed based on the colour
ntensity.a with human epithelial-2 cells as substrate. (A) Homogenous antinuclear antibody
omosomal regions. (B) Speckled ANA pattern. Arrows are pointing at mitotic cells
 staining.
2.4. ELISA tests
The serum samples were analysed in a 1:201 dilution with
four different ELISAs (Euroimmun). The ELISAs used were the
anti-dsDNA ELISA for detection of autoantibodies against double-
stranded genomic DNA, the anti-nucleosomes ELISA for the
detection of autoantibodies against nucleosomes, the anti-dsDNA-
NcX ELISA for the detection of autoantibodies against dsDNA
complexed with nucleosomes, and the anti-ENA ProﬁlePlus 1 ELISA
for the detection of antibodies against six different ENAs, namely
nRNP/Sm, Sm,  SS-A/Ro-60, SS-B, Scl-70 and Jo-1. All assays were
performed according to the manufacturer’s instructions with the
exception of the anti-human-IgG conjugate, which was exchanged
for peroxidase-conjugated rabbit anti-dog IgG (Euroimmun). Pho-
tometric measurement of the colour intensity was performed using
an automated reader (TECAN) in combination with Magellan soft-
ware.
2.5. CLIFT
Sera positive for anti-dsDNA with ELISA or LIA were further
investigated with the CLIFT at the Department of clinical immunol-
ogy at Uppsala University Hospital. Samples were diluted 1:10, and
staining was performed on C. luciliae substrate (ImmunoConcept)
according to the hospital laboratory protocol at Uppsala University
Hospital intended for human patients, but with the exchange of the
anti-human conjugate to the ﬂuorescein isothiocyanate-coupled
rabbit anti-dog IgG antibody (Sigma–Aldrich, Stockholm, Sweden)
used in the IIF-ANA test described above, and with the same dilu-
tion (1:100) as used in the IIF-ANA test. The microscope slides were
evaluated by an experienced interpreter (JR).
2.6. Statistical analysis
Data were assembled using Microsoft® Excel® 2011, version
14.4.5 and software R version 3.0.2 (R Foundation for Statistical
Computing). Statistical analyses were performed using Vassarstats
(http://vassarstats.net/odds2×2.html) and software R. To compare
the ANAH and the ANAS groups for speciﬁc ANA, we  used the highest
observed value in the healthy group as a cut-off value and com-
pared the frequency of positive cases between the groups with the
Fisher exact probability test (two-tailed). Kendall’s tau () was cal-
culated to assess the degree of correlation between the LIA and
ELISA assays using R package stats (v. 3.0.2). p-Values less than 0.05
were considered as signiﬁcant.
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ositive with a homogenous pattern (n = 68); Sp, ANA positive with a speckled patt
. Results
.1. IIF-ANA test
The IIF-ANA test results (positive/negative) obtained from
weden were conﬁrmed in all the samples at repeated analyses in
ermany. Of the 210 serum samples from ANApos dogs that were
nalysed with regards to IIF-ANA pattern and ANA speciﬁcity, 68
ere classiﬁed as ANAH, 141 as ANAS and one sample was not pos-
ible to classify as ANAH or ANAS and was therefore excluded from
urther analyses. In the healthy control group, one serum sample
as ANA positive with a speckled pattern. In total 266 canine sera
rom 239 dogs with suspicion of autoimmune disease (68 ANAH,
41 ANAS, 30 ANAneg) and from 27 healthy dogs were evaluated and
ompared with regards to speciﬁc ANA reactivity. The breed and sex
istribution in the three ANA groups are presented in Table 1. Note
hat the healthy group is not included in the table, since informa-
ion about sex and breed was not available. Sera from eight dogs
hat were sampled twice, having had 35 to 480 days in between,
howed the same IIF-ANA pattern at both occasions..2. Speciﬁc antigen reactivity
Speciﬁc ANA reactivities measured in the LIA in individual dogs
re presented as a heat map  (Fig. 2), which allows the ability to seeA) for all the dogs included in the study (n = 266). Ho, antinuclear antibody (ANA)
 = 141); Ne, ANA negative (n = 30); He, healthy dogs (n = 27).
combinations of reactivities in individual dogs and dogs with simi-
lar ANA speciﬁcity. A heat map  for the ELISA results is presented as
supplementary material (Figure S1). Findings of particular interest
are discussed in the following sections.
3.2.1. Antibodies to dsDNA, nucleosomes, and histones
The results from the LIA and the ELISAs for dsDNA, nucleosomes
and histones for the four different groups of dogs are presented in
Fig. 3. Dogs in the ANAH group had, compared to the other groups,
most frequently high levels of anti-dsDNA and anti-nucleosome
ANA (measured as OD and band intensity in the ELISAs and LIA,
respectively). The number of dogs in the ANAH group with anti-
dsDNA reactivity above that observed in the healthy group was
9 (13%) in the LIA and 22 (32%) in the ELISA, respectively. This is
a signiﬁcant difference compared to the ANAS group (Fisher’s test
p = 0.002 for LIA, p < 0.001 for ELISA) where the corresponding num-
ber of dogs were 3 (2.1%) in the LIA and 15 (11%) in the ELISA. In
total sera from 39 dogs (22 ANAH, 16 ANAS, one ANAneg) had anti-
dsDNA reactivity in the LIA and/or the ELISA. Of  these, 10 sera (9
ANAH, one ANAS) were positive against dsDNA with CLIFT (Fig. 4).
All the 12 healthy control samples were negative.The number of dogs in the ANAH group with anti-nucleosome
reactivity above that observed in the healthy group was  59 (87%)
in the LIA and 64 (94%) in the ELISA, a signiﬁcant difference com-
pared to the ANAS group (p < 0.001 for LIA and ELISA) where the
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Table  1
Number of dogs (%) of each breed and sex distributed according to the three main ANA patterns.
ANAneg ANAH ANAS Total
German Shepherd Dog 3 (10) 4 (5.9) 26 (18) 33 (14)
NSDTR  2 (6.7) 17 (25) 13 (9.2) 32 (13)
Cocker  Spaniel 0 (0.0) 2 (2.9) 16 (11) 18 (7.5)
Mixed-breed 0 (0.0) 1 (1.5) 11 (7.8) 12 (5.0)
Golden  Retriever 2 (6.7) 2 (2.9) 7 (5.0) 11 (4.6)
Cairn  Terrier 1 (3.3) 5 (7.4) 2 (1.4) 8 (3.3)
Jack  Russel 1 (3.3) 4 (5.9) 1 (0.7) 6 (2.5)
Others  21 (70) 33 (49) 65 (46) 119 (50)
Total  30 (100) 68 (100) 141 (100) 239 (100)
Females  12 (40) 45 (66) 66 (47) 123 (51)
Males  18 (60) 22 (32) 74 (52) 114 (48)
Unknown 0 (0.0) 1 (1.5) 1 (0.71) 2 (0.84)
All dogs were suspected to have autoimmune disease. Breeds with n ≥ 5 presented as individual breeds, dogs of other breeds (n < 5) and unknown breeds (n = 9) presented as
others.
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3.2.2. Antibodies to extractable nuclear antigens
The results from the LIA and ELISAs for the extractable nuclear
antigens RNP (RNP-A, RNP-C, RNP-70), Sm,  nRNP/Sm, SS-A/Ro-60,
SS-A/Ro-52, SS-B, Scl-70 and Jo-1 are presented in Fig. 5.
Dogs in the ANAS group had, compared to the other groups, most
frequently high levels of anti-RNP and/or anti-Sm antibodies. The
number of dogs in the ANAS group with anti-nRNP/Sm reactivity
above that observed in the healthy group was 32 (23%) in the LIA
and 36 (26%) in the ELISA, a signiﬁcant difference compared to the
ANAH group (p < 0.001 for LIA and ELISA) where the corresponding
number of dogs was  1 (1.5%) in both the LIA and the ELISA. Compar-
ing the frequency of dogs with values above that observed in the
omplexed with NUC (dsDNA-NcX). Results from line immunoassay (LIA) and ELISA
ibody (ANA) positive with a homogenous pattern; Sp, ANA positive with a speckled
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ealthy group for the remaining ENAs, the frequency was higher
n the ANAS group than in the ANAH group for RNP-A (p < 0.001 for
IA), RNP-C (p = 0.007 for LIA), RNP-70 (p < 0.001 for LIA) and Sm
p < 0.001 for LIA, p = 0.002 for ELISA). There was no difference in
requency between the ANAH and ANAS group for the remaining
ntigens but some dogs had reactivities above that observed in the
ealthy groups against SS-A, SS-B, Jo-1, Scl-70, and individual dogs
ad a particularly strong reactivity (Fig. 5). One dog had strong reac-
ivity for anti-SS-A as well as anti-SS-B antibodies measured both
ith LIA and ELISA (Figs. 2, 5, S1 and S2). Another dog had strong
nti-SS-A reactivity conﬁrmed by both methods, while yet another
og had single SS-A reactivity only measured in the ELISA but not
onﬁrmed in the LIA (Figure S2). Antibodies against Sm and RNP
ntibodies were often observed in the same individuals (Figs. 2 and
1).
.2.3. Antibodies to remaining antigens
Antibodies against M2,  PCNA, RIB, CENP-B and PM-Scl, were only
easured with the LIA. The results are presented in Fig. 6. Individ-
al dogs in the ANAS group had clear anti-PM-Scl or anti-PCNA
eactivity.
. Discussion
With the use of human commercial LIA and ELISA tests we  iden-
iﬁed several speciﬁc ANA in serum samples from dogs sampled
or IIF-ANA testing. Further, we found that the reactivity against
peciﬁc nuclear antigens was associated with individual IIF-ANA
atterns. Anti-dsDNA and anti-nucleosome antibodies were most
requently observed in the ANAH group which is in agreement with
bservations in humans (von Mühlen and Tan, 1995). Findings of
nti-DNA and anti-nucleosome antibodies also in some dogs with
n IIF-ANA speckled pattern might indicate that these dogs actually
ave a mixed IIF-ANA pattern.
Previous investigations of anti-dsDNA antibodies in dogs have
ielded inconclusive results. While some authors have identiﬁed
nti-dsDNA antibodies (Fournel et al., 1992; Monier et al., 1992),
thers have investigated a large number of ANA positive dogs
or anti-dsDNA antibodies with negative results (Monestier et al.,
995; Hansson and Karlsson-Parra, 1999). Immunopathology 168 (2015) 233–241
We  could conﬁrm anti-dsDNA reactivity with CLIFT in 10 out
of 39 sera that were positive in the ELISA and/or the LIA. In sera
with a homogenous pattern in the HEp-2 IIF, 9 out of 22 were CLIFT
positive. The CLIFT staining pattern was  exactly the same as with
human SLE sera. The CLIFT has previously been applied in canine
studies, mostly with negative results (Brinet et al., 1988; Hansson
and Karlsson-Parra, 1999), but Fournel et al. (1992) detected anti-
dsDNA antibodies in two dogs with CLIFT. In our study the ﬁve
samples with highest antibody levels in the ELISA were conﬁrmed
to be anti-dsDNA positive by CLIFT, however, there was no clear
correlation between the CLIFT result and the antibody levels in the
ELISA and the LIA for the rest of the samples. It is well known from
human studies, that there is a considerable discordance between
anti-dsDNA detection methods (Haugbro et al., 2004; Enocsson
et al., 2015). Different assays can detect different subpopulations
of anti-dsDNA autoantibodies with different avidity. ELISAs also
detect low avidity anti-dsDNA antibodies, which can occur in other
diseases than SLE. There are additional explanations for discrepant
results in different assays, for example that the source and the pre-
sentation of the antigens vary between assays, and that the reaction
conditions differ (Smeenk, 2002; Riboldi et al., 2005). Consequently,
it is not surprising that we could not conﬁrm anti-dsDNA reactivity
in all dogs. CLIFT has lower sensitivity than enzyme immunoas-
says, but is highly speciﬁc for anti-dsDNA reactivity in SLE patients
(Haugbro et al., 2004; Enocsson et al., 2015).
The majority of dogs with anti-dsDNA reactivity also had anti-
nucleosome reactivity and reactivity against dsDNA complexed
with nucleosomes. Monestier et al. (1995) previously investigated
reactivity against nucleosomes in 43 dogs with SLE and found no
signiﬁcant difference in anti-nucleosome reactivity between SLE
and control dogs. However the mean value in the SLE dogs was
slightly higher than in controls, indicating that although not sig-
niﬁcant at group level, individual SLE dogs might have had high
anti-nucleosome antibody levels. Anti-nucleosome antibodies have
been suggested to be a better diagnostic marker than anti-dsDNA
antibodies in human SLE (Bizzaro et al., 2012) and the ELISA with
dsDNA complexed with nucleosomes might be superior to anti-
dsDNA and anti-nucleosome ELISAs (Biesen et al., 2011). Our results
show that many ANA positive dogs, mainly ANAH dogs, have these
antibodies, but if any of these assays can be used in the diagnosis
of canine SLE needs to be further investigated.
Previous work in dogs have reported anti-histone antibodies to
be common in canine SLE (Costa et al., 1984; Monier et al., 1992;
Monestier et al., 1995) and therefore have been suggested to be
included in the criteria for canine SLE (Chabanne et al., 1999). In
comparison, we observed anti-histone antibodies in some ANApos
dogs, but at a lower frequency. Since clinical information was
not available for the dogs in our study it is not possible to know
how many of the canine patients suffered from SLE. This might
explain the lower frequency compared to studies including only
SLE dogs. Furthermore, antigens and exposure of different epitopes
might vary between assays, a circumstance that might inﬂuence
the results.
Antibodies against RNP and Sm were mostly present in the
ANAS group, also in agreement with observations in humans (von
Mühlen and Tan, 1995; Wiik et al., 2010). A few dogs in the ANAH
group had anti-RNP and anti-Sm reactivity, but they also had anti-
nucleosome reactivity, which explains the homogenous pattern.
In agreement with human observations (Sherer et al., 2004), anti-
RNP and anti-Sm antibodies were often present together in the
same dog. Anti-Sm antibodies have high speciﬁcity for human SLE,
while antibodies against RNP without anti-Sm can be associatedalso occur in other systemic rheumatic diseases like myositis and
systemic sclerosis. Both anti-RNP and anti-Sm antibodies have pre-
viously been identiﬁed in dogs (Costa et al., 1984; Hubert et al.,
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etween the assays. Ho, antinuclear antibody (ANA) positive with a homogenous p
988; Fournel et al., 1992; Welin Henriksson et al., 1998; Hansson-
amlin and Rönnelid, 2010). Speciﬁc ANA that could be detected
n only a few dogs were anti-SS-A, anti-SS-B, anti-Scl-70, anti-Jo1
nd anti-PCNA. To our knowledge, speciﬁc ANA against Scl-70 and
ntibodies to the cytoplasmic antigen Jo-1 have not previously been
dentiﬁed in dogs. Anti-Scl-70 antibodies are associated with sys-
emic sclerosis (Shero et al., 1986) and anti-Jo-1 with polymyositis
Nishikai and Reichlin, 1980) in humans. Suspected anti-PCNA anti-
odies have previously been reported in one dog with SLE-related
isease (Goudswaard et al., 1993). In humans, anti-PCNA antibod-
es are associated with, but not speciﬁc for SLE (Mahler et al., 2012).
uman studies have indicated that multiple reactivities are more
ommon in SLE than other SLE-related disorders and can also be immunoassay (LIA) and ELISA presented. Note that the some of the antigens vary
; Sp, ANA positive with a speckled pattern; Ne, ANA negative; He, healthy dogs.
associated with more severe SLE disease (Notman et al., 1975; Boey
et al., 1988). In our study we  observed that some dogs had high anti-
body levels against several antigens, but the clinical signiﬁcance of
this is not known.
It was  not possible to detect the speciﬁc ANA in all the ANApos
dogs. One reason could be that the 43 kDa protein known as hnRNP-
G (Costa et al., 1984; Soulard et al., 1991) and the type-2 antigen
(Costa et al., 1984; Fournel et al., 1992), which are thought to be
important canine antigens, were not included in the assays.Several of our results are in agreement with previous work about
ANA speciﬁcity in dogs. However, comparing frequency of positive
cases between studies is not possible, since the inclusion criteria,
methods and interpretation of positive samples vary a lot between
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Aig. 6. Antibody reactivity against M2,  PCNA, RIB, CENP B and PM-Scl in the line im
p,  ANA positive with a speckled pattern; Ne, ANA negative; He, healthy dogs.
tudies. Here we used the highest observed value in the healthy
roup as a cut-off to compare the two ANApos groups. It should be
oted that the distribution of age, sex, and breeds of the healthy
ogs was not known so this group might not be well representa-
ive of the diseased group. We  would not recommend a cut-off for a
linical test being based on the results presented here. To establish
 cut-off was not the aim of our study but instead to discover high
alues of speciﬁc ANA in individual dogs. Even if a large represen-
ative control group was to be analysed, establishing a cut-off for a
linical test would be a challenge, especially for the LIA, because the
ata are not normally distributed and not entirely continuous. The
IA is semi-quantitative, and small differences in observed values
ight be of little importance.
ELISA and LIA are routinely used in human diagnostics for the
etection of speciﬁc autoantibodies. Both techniques are quan-
itative (ELISA) or at least semi-quantitative (LIA), automatable
nd therefore suitable for large scale testing. The evaluation is
erformed using special software making it easier to obtain stan-
ardised results. Up to now, no such techniques are used routinely
or ANA diagnostics in dogs but both might be adapted in the future.
owever, both assays are prototypes and have to be validated and
djusted accordingly. In a few dogs the ELISA detected high lev-
ls of antibodies that were not conﬁrmed with the LIA. The reason
or this is not obvious but ELISAs are known to be very sensitive
n detecting antibodies, but to have lower speciﬁcity compared to
ther methods, while immunoblot techniques sometimes fail to
etect antibodies against some antigens like SS-A and Scl-70 (Phan
t al., 2002; Orton et al., 2004). This is a likely explanation to the
eak agreement observed for these two antigens in our study.
Further research is also needed to relate the results for speciﬁc
ntigens in ELISA and LIA to clinical ﬁndings. The lack of clinical
ata for the majority of dogs is a limitation of our study. Clinical
ecords were available for some of the dogs, but there were too
ew dogs to speculate about a connection between speciﬁc ANA
nd clinical signs. Since speciﬁc ANA are associated with particular
utoimmune diseases and symptoms in humans, ﬁnding similar
ssociations in dogs would be very useful. There is a need for more
peciﬁc tests for autoimmune diseases in dogs, and future research
hould aim at correlating speciﬁc ANA with particular clinical signs.
. Conclusion
We  investigated sera from a large number of dogs for speciﬁc
NA with commercial assays originally developed for the detec-
ion of human ANA. Several speciﬁc ANA previously described in
ogs were identiﬁed, conﬁrming results from previous studies. In
ndividual dogs we also identiﬁed ANA of importance in human
edicine but not previously described in dogs. Further, different
ypes of IIF-ANA patterns were shown to be associated with speciﬁc
NA reactivities.oassay (LIA). Ho, antinuclear antibody (ANA) positive with a homogenous pattern;
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